National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings, 48319 [2018-20666]
Download as PDF
<![CDATA[
amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 83, No. 185 / Monday, September 24, 2018 / Notices
would benefit from harmonization,
consistency, clarity, simplification, and/
or coordination.
The SACHRP meeting will open to the
public at 8:30 a.m., on Tuesday, October
16, 2018, followed by opening remarks
from Dr. Jerry Menikoff, Director of
OHRP and Dr. Stephen Rosenfeld,
SACHRP Chair.
The SAS and SOH subcommittees
will present their recommendations
regarding the description of ‘‘key
information,’’ as required by the revised
Common Rule at § 46.116(a)(5)(i). This
will be followed by a discussion of
recommendations of the interpretation
of the revised Common Rule’s
exemptions § 46.104(d)(1) and (2) for
HHS funded research. Lastly, the
committee will continue its July
discussions on the Office of Inspector
General Report, July 7, 2017: ‘‘OHRP
Generally Conducted Its Compliance
Activities Independently, But Changes
Would Strengthen Its Independence.’’
The Wednesday, October 17, meeting
will begin at 8:30 a.m. The SAS
subcommittee will present and discuss
recommendations on the interpretation
of ‘‘reasonably available’’ at § 46.408(b),
as well as discuss issues surrounding
payment of subjects for participation in
research. Modifications to the previous
day’s work will be discussed and
finalized. The meeting will adjourn at
approximately 4:00 p.m., October 17,
2018.
Time for public comment sessions
will be allotted both days. On-site
registration is required for participation
in the live public comment session.
Note that public comment must be
relevant to topics currently being
addressed by the SACHRP. Individuals
submitting written statements as public
comment should email or fax their
comments to SACHRP at SACHRP@
hhs.gov at least five business days prior
to the meeting.
Public attendance at the meeting is
limited to space available. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify one of
the designated SACHRP points of
contact at the address/phone number
listed above at least one week prior to
the meeting.
Dated: September 14, 2018.
Julia G. Gorey,
Executive Director, Secretary’s Advisory
Committee on Human Research Protections.
[FR Doc. 2018–20676 Filed 9–21–18; 8:45 am]
BILLING CODE 4150–36–P
VerDate Sep<11>2014
17:40 Sep 21, 2018
Jkt 244001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meetings
48319
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: September 18, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–20666 Filed 9–21–18; 8:45 am]
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; T32
Institutional Training Grants.
Date: October 10, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Canopy by Hilton, 940 Rose Avenue,
North Bethesda, MD 20852.
Contact Person: Nakia C. Brown, Ph.D.,
Scientific Review Officer, 6701 Democracy
Blvd., RM 816, Bethesda, MD 20892, 301–
827–4905, brownnac@mail.nih.gov.
Name of Committee: Arthritis and
Musculoskeletal and Skin Diseases Initial
Review Group; Arthritis and Musculoskeletal
and Skin Diseases Clinical Trials Review
Committee.
Date: October 16–17, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn, 7301 Waverly
Street, Bethesda, MD 20814.
Contact Person: Nakia C. Brown, Ph.D.,
NIAMS/Scientific Review Officer, 6701
Democracy Blvd., RM 816, Bethesda, MD
20892, 301–827–4905, brownnac@
mail.nih.gov.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; AMSC
Member Conflict.
Date: October 29, 2018.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Democracy One, 6701 Democracy
Blvd., Bethesda, MD 20892.
Contact Person: Yasuko Furumoto, Ph.D.,
NIAMS/Scientific Review Officer, 6701
Democracy Blvd., RM 816, Bethesda, MD
20892, 301–451–6520, yasuko.furumoto@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Yogikala Prabhu, Ph.D., 301–761–7789;
prabhuyo@niaid.nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
A New Class of Immunomodulatory
Drugs for Multiple Sclerosis
Description of Technology: Multiple
sclerosis (MS) is an autoimmune disease
caused by activated autoimmune T
lymphocytes in patients resulting in
inflammatory demyelination in the
central nervous system. Current
treatments are focused on functional
control of these activated autoimmune T
cells, but these treatments are nonspecific T cell inhibitors and have
serious, sometimes fatal side effects. A
specific therapy aimed at eliminating
these autoimmune T cells through
restimulation-induced cell death (RICD)
could cure the disease and overcome the
fatal side effects of current therapies.
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 83, Number 185 (Monday, September 24, 2018)]
[Notices]
[Page 48319]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-20666]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin
Diseases; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Arthritis and
Musculoskeletal and Skin Diseases Special Emphasis Panel; T32
Institutional Training Grants.
Date: October 10, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD
20852.
Contact Person: Nakia C. Brown, Ph.D., Scientific Review
Officer, 6701 Democracy Blvd., RM 816, Bethesda, MD 20892, 301-827-
4905, [email protected].
Name of Committee: Arthritis and Musculoskeletal and Skin
Diseases Initial Review Group; Arthritis and Musculoskeletal and
Skin Diseases Clinical Trials Review Committee.
Date: October 16-17, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Garden Inn, 7301 Waverly Street, Bethesda, MD
20814.
Contact Person: Nakia C. Brown, Ph.D., NIAMS/Scientific Review
Officer, 6701 Democracy Blvd., RM 816, Bethesda, MD 20892, 301-827-
4905, [email protected].
Name of Committee: National Institute of Arthritis and
Musculoskeletal and Skin Diseases Special Emphasis Panel; AMSC
Member Conflict.
Date: October 29, 2018.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Democracy One, 6701 Democracy Blvd., Bethesda, MD 20892.
Contact Person: Yasuko Furumoto, Ph.D., NIAMS/Scientific Review
Officer, 6701 Democracy Blvd., RM 816, Bethesda, MD 20892, 301-451-
6520, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.846,
Arthritis, Musculoskeletal and Skin Diseases Research, National
Institutes of Health, HHS)
Dated: September 18, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-20666 Filed 9-21-18; 8:45 am]
BILLING CODE 4140-01-P
